DORNASE ALFA and INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS

Overview

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is the #1 most commonly reported adverse reaction for DORNASE ALFA, manufactured by Genentech, Inc.. There are 2,282 FDA adverse event reports linking DORNASE ALFA to INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS. This represents approximately 7.7% of all 29,815 adverse event reports for this drug.

Patients taking DORNASE ALFA who experience infective pulmonary exacerbation of cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is moderately reported among DORNASE ALFA users, representing a notable but not dominant share of adverse events.

Other Side Effects of DORNASE ALFA

In addition to infective pulmonary exacerbation of cystic fibrosis, the following adverse reactions have been reported for DORNASE ALFA:

• CYSTIC FIBROSIS — 1,727 reports
• HOSPITALISATION — 1,289 reports
• PNEUMONIA — 1,269 reports
• COUGH — 980 reports
• OFF LABEL USE — 934 reports
• INFECTION — 922 reports
• NO ADVERSE EVENT — 919 reports
• DYSPNOEA — 898 reports
• CONDITION AGGRAVATED — 601 reports
• HEADACHE — 536 reports

Other Drugs Associated with INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS

The following drugs have also been linked to infective pulmonary exacerbation of cystic fibrosis in FDA adverse event reports:

Does DORNASE ALFA cause INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS?

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS has been reported as an adverse event in 2,282 FDA reports for DORNASE ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS with DORNASE ALFA?

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS accounts for approximately 7.7% of all adverse event reports for DORNASE ALFA, making it one of the most commonly reported side effect.

What should I do if I experience INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS while taking DORNASE ALFA?

If you experience infective pulmonary exacerbation of cystic fibrosis while taking DORNASE ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages